6. パーキンソン病 Parkinson disease Clinical trials / Disease details


臨床試験数 : 2,307 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

  
9 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-000041-40-NL
(EUCTR)
22/02/202210/11/2021A study to investigate the effects of repeated low doses of psilocybin and ketamine on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of actionA study to investigate the effects of repeated low doses of psilocybin and ketamine on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action - Microdosing and Parkinson’s disease Parkinson's disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: Psilocybin
INN or Proposed INN: Psilocybine
Product Name: Ketamine
INN or Proposed INN: KETAMINE
Maastricht UniversityNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
34Phase 2Netherlands
2NCT04944017
(ClinicalTrials.gov)
November 23, 202122/6/2021Ketamine for the Treatment of Depression in Parkinson's DiseaseKetamine for the Treatment of Depression in Parkinson's Disease (KET-PD)Parkinson's Disease;DepressionDrug: Ketamine Infusion;Other: Placebo - Saline InfusionYale UniversityFox (Michael J.) Foundation for Parkinson's ResearchRecruiting40 Years80 YearsAll56Phase 2United States
3NCT04912115
(ClinicalTrials.gov)
October 5, 202125/5/2021Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced DyskinesiaA Multi-Center, Phase II, Randomized, Double-Blind, Prospective, Active Placebo- Controlled Trial of Sub-Anesthetic Intravenous Infusion of Ketamine to Treat Levodopa- Induced Dyskinesia in Subjects With Parkinson's DiseaseDyskinesias;Movement Disorders;Central Nervous System Diseases;Nervous System Diseases;Neurologic ManifestationsDrug: Ketamine;Drug: MidazolamPharmaTher Inc.NULLSuspended30 Years85 YearsAll30Phase 2United States
4NCT03858270
(ClinicalTrials.gov)
April 1, 20192/10/2018Inhibition of a-synuclein Cell-cell Transmission by NMDAR Blocker, MemantineInhibition of a-synuclein Cell-cell Transmission by NMDAR Blocker, MemantineParkinson DiseaseDrug: Memantine;Other: PlaceboWayne State UniversityNULLRecruiting45 Years85 YearsAll50Phase 3United States
5NCT01785628
(ClinicalTrials.gov)
August 201024/6/2011The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's DiseaseParkinson's Disease With DementiaDietary Supplement: Sarcosine Capsule;Dietary Supplement: Placebo CapsuleChina Medical University HospitalNational Science Council, TaiwanCompletedN/AN/AAll30N/ATaiwan
6NCT00163085
(ClinicalTrials.gov)
May 20059/9/2005The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's DiseaseA Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Explore The Efficacy And Safety Of The NR2B NMDA Antagonist CP-101,606 In Patients With Idiopathic Parkinson's DiseaseParkinson's DiseaseDrug: NR2B NMDA Antagonist CP-101,606 (traxoprodil)PfizerNULLCompleted30 Years80 YearsBoth12Phase 2United States
7NCT00375778
(ClinicalTrials.gov)
April 200512/9/2006Parkinson's Disease Evaluated by PET and the Effect of MemantineParkinson's Disease Evaluated by Positron Emission Tomography and the Effect of the NMDA Receptor Antagonist MemantineParkinson's DiseaseDrug: memantine (drug)University of AarhusLundbeck FoundationCompleted50 Years70 YearsBoth12N/ADenmark
8NCT00001929
(ClinicalTrials.gov)
March 19993/11/1999Treatment of Parkinson's Disease With EliprodilNMDA-Receptor Blockade With Eliprodil in Parkinson's DiseaseMovement Disorders;Parkinson DiseaseDrug: EliprodilNational Institute of Neurological Disorders and Stroke (NINDS)NULLCompletedN/AN/ABoth20Phase 2United States
9NCT00001365
(ClinicalTrials.gov)
July 19933/11/1999Dextromethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous SystemNMDA Receptor Antagonist Treatment of Neurodegenerative DiseaseNeurodegenerative Disease;Parkinson's DiseaseDrug: dextromethorphanNational Institute of Neurological Disorders and Stroke (NINDS)NULLCompletedN/AN/ABoth42Phase 2United States